4D Molecular Therapeutics, Inc. (FDMT) Return on equity 2020–2025
4D Molecular Therapeutics, Inc. (FDMT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-27.7%FY2025 · since FY2020: -22.1% → -27.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -27.7% | +3.8 pp |
| FY2024 | -31.5% | +1.3 pp |
| FY2023 | -32.8% | +13.7 pp |
| FY2022 | -46.5% | -24.1 pp |
| FY2021 | -22.3% | -0.2 pp |
| FY2020 | -22.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice